Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2006 2
2007 1
2008 2
2009 3
2010 1
2011 2
2012 2
2013 3
2014 3
2015 4
2017 5
2018 5
2019 6
2020 5
2021 3
2022 7
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Loureirin B protects against cerebral ischemia/reperfusion injury through modulating M1/M2 microglial polarization via STAT6 / NF-kappaB signaling pathway.
Li R, Jia H, Si M, Li X, Ma Z, Zhu Y, Sun W, Zhu F, Luo S. Li R, et al. Eur J Pharmacol. 2023 Aug 15;953:175860. doi: 10.1016/j.ejphar.2023.175860. Epub 2023 Jun 16. Eur J Pharmacol. 2023. PMID: 37331681 Review.
The latest research indicates that modulating microglial polarization from M1 to M2 phenotype may be a coping therapy for ischemic stroke. The present study thereby evaluated the effects of loureirin B (LB), a monomer compound extracted from Sanguis Draconis flavone …
The latest research indicates that modulating microglial polarization from M1 to M2 phenotype may be a coping therapy for ischemic stroke. T …
Loureirin B Exerts its Immunosuppressive Effects by Inhibiting STIM1/Orai1 and K(V)1.3 Channels.
Shi S, Zhao Q, Ke C, Long S, Zhang F, Zhang X, Li Y, Liu X, Hu H, Yin S. Shi S, et al. Front Pharmacol. 2021 Jun 25;12:685092. doi: 10.3389/fphar.2021.685092. eCollection 2021. Front Pharmacol. 2021. PMID: 34248635 Free PMC article.
Loureirin B (LrB) is a constituent extracted from traditional Chinese medicine Resina Draconis. ...Further experiments showed that Loureirin B directly inhibited STIM1/Orai1 channel in a dose-dependent manner. ...
Loureirin B (LrB) is a constituent extracted from traditional Chinese medicine Resina Draconis. ...Further experiments showed …
Loureirin B alleviates cardiac fibrosis by suppressing Pin1/TGF-beta1 signaling.
Cheng M, Yang Z, Li R, Wu G, Zhang C. Cheng M, et al. Eur J Pharmacol. 2022 Mar 5;918:174791. doi: 10.1016/j.ejphar.2022.174791. Epub 2022 Jan 28. Eur J Pharmacol. 2022. PMID: 35093323
Furthermore, loureirin B treatment inhibited the increased fibroblast activation and collagen synthesis induced by Ang II in CFs. In addition, loureirin B inhibited increased expression of TGF-beta1 and Pin1 induced by Ang II or TAC. ...
Furthermore, loureirin B treatment inhibited the increased fibroblast activation and collagen synthesis induced by Ang II in C …
Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways.
Fang H, Ding Y, Xia S, Chen Q, Niu B. Fang H, et al. Eur J Pharmacol. 2022 Dec 5;936:175377. doi: 10.1016/j.ejphar.2022.175377. Epub 2022 Nov 5. Eur J Pharmacol. 2022. PMID: 36347320
Loureirin B (LB), a natural product derived from Sanguis draconis, has hypoglycemic effects in diabetic mice. ...The results showed that LB could promote cell proliferation and reduce apoptosis of Ins-1 cells. Loureirin B (LB), a natural product derive …
Loureirin B (LB), a natural product derived from Sanguis draconis, has hypoglycemic effects in diabetic mice. ...The results s …
Loureirin B downregulates osteoclast differentiation of bone marrow macrophages by targeting the MAPK signaling pathway.
Zhang J, Mo L, Huang H, Xu J, Fan Y, Li W, Wang H, Zhou C, Fang H, He W, Chen Z, Liu Y. Zhang J, et al. Sci Rep. 2022 Aug 23;12(1):14382. doi: 10.1038/s41598-022-18287-5. Sci Rep. 2022. PMID: 35999378 Free PMC article.
Excessive absorption of osteoclasts will break the balance between osteoclasts and osteoblasts, leading to bone loss, decreased bone density, and increased bone fragility. We have shown that Loureirin B (LrB) can inhibit osteoclasts. In this study, we demonstrated t …
Excessive absorption of osteoclasts will break the balance between osteoclasts and osteoblasts, leading to bone loss, decreased bone density …
Loureirin B promotes insulin secretion through inhibition of K(ATP) channel and influx of intracellular calcium.
Sha Y, Zhang Y, Cao J, Qian K, Niu B, Chen Q. Sha Y, et al. J Cell Biochem. 2018 Feb;119(2):2012-2021. doi: 10.1002/jcb.26362. Epub 2017 Sep 11. J Cell Biochem. 2018. PMID: 28817206
The development of new diabetes drugs continues to be explored. Loureirin B, a flavonoid, extracted from Dracaena cochinchinensis, has been confirmed to increase insulin secretion and decrease blood glucose levels. For searching the promotion of insulin secretion wi …
The development of new diabetes drugs continues to be explored. Loureirin B, a flavonoid, extracted from Dracaena cochinchinen …
Loureirin B Alleviates Myocardial Ischemia/Reperfusion Injury via Inhibiting PAI-1/TGF-beta1/Smad Signaling Pathway.
Kong F, Zhao M. Kong F, et al. Evid Based Complement Alternat Med. 2022 Apr 30;2022:9128210. doi: 10.1155/2022/9128210. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35535157 Free PMC article.
Myocardial ischemia/reperfusion (MI/R) injury is a common clinical problem after myocardial infarction without effective therapy. Loureirin B (LrB) is a kind of flavonoid with anti-inflammatory and antifibrotic activities. ...
Myocardial ischemia/reperfusion (MI/R) injury is a common clinical problem after myocardial infarction without effective therapy. Loureir …
Loureirin B protects against obesity via activation of adipose tissue omega3 PUFA-GPR120-UCP1 axis in mice.
Liu M, Zhang JF, Zhu WL, Liu H, Jia X. Liu M, et al. Biochem Biophys Res Commun. 2022 Dec 3;632:139-149. doi: 10.1016/j.bbrc.2022.09.096. Epub 2022 Oct 3. Biochem Biophys Res Commun. 2022. PMID: 36209582
Current lifestyle interventions and drug treatment for obesity seem insufficient. Here, we show that Loureirin B (LB), a major flavonoid molecule extracted from Sanguis Draxonis, prevents diet-induced obesity and ameliorates concomitant metabolic abnormalities inclu …
Current lifestyle interventions and drug treatment for obesity seem insufficient. Here, we show that Loureirin B (LB), a major …
Loureirin B inhibits fibroblast proliferation and extracellular matrix deposition in hypertrophic scar via TGF-beta/Smad pathway.
Bai X, He T, Liu J, Wang Y, Fan L, Tao K, Shi J, Tang C, Su L, Hu D. Bai X, et al. Exp Dermatol. 2015 May;24(5):355-60. doi: 10.1111/exd.12665. Epub 2015 Mar 9. Exp Dermatol. 2015. PMID: 25683490
Loureirin B also affected mRNA levels of major MMPs and TIMPs in TGF-beta1-stimulated fibroblasts. ...These findings suggest that loureirin B is a potential therapeutic compound for HS treatment....
Loureirin B also affected mRNA levels of major MMPs and TIMPs in TGF-beta1-stimulated fibroblasts. ...These findings suggest t …
Loureirin B activates GLP-1R and promotes insulin secretion in Ins-1 cells.
Ding Y, Xia S, Zhang H, Chen Q, Niu B. Ding Y, et al. J Cell Mol Med. 2021 Jan;25(2):855-866. doi: 10.1111/jcmm.16138. Epub 2020 Dec 10. J Cell Mol Med. 2021. PMID: 33300675 Free PMC article.
Loureirin B (LB) is a natural product derived from Sanguis draconis, which has hypoglycaemic effects. ...
Loureirin B (LB) is a natural product derived from Sanguis draconis, which has hypoglycaemic effects. ...
55 results